Moatly / Stocks / INCY

Incyte (INCY) — what is it worth?

$120.30 · $24.5B market cap · Biotechnology
Scored from reported financial statements. Data as of 2026-11-11.
Moat
88
Durability of advantage
Management
90
Returns and capital use
Margin of safety
20
Price against value
Buy price
$52.24
Consensus of three methods
Intrinsic value
$48.47
What the business is worth
Margin of safety price
$24.23
Intrinsic value less 50%
10-CAP price
$34.58
Ten times owner earnings
Payback time price
$52.24
Eight years of free cash flow
Moatly AI Insight

Incyte is scored 88 for moat and 90 for management. The management score rests on a return on invested capital of 20.6% and a gross margin of 92.8% — figures that describe a business turning capital into profit efficiently. Debt sits at 0.01x equity.

The valuation runs on assumptions chosen to understate rather than flatter. Growth is modelled at 14.0% a year, the rate measured from the filings. The exit multiple assumed is 28.1x. That produces an intrinsic value of $48.47, a 10-CAP price of $34.58 and a payback time price of $52.24, with the value zone set at the highest of the three, $52.24. Today's price of $120.30 is 130% above it.

A wonderful business at the wrong price is still the wrong price. Incyte scores well on the business and poorly on the entry point, which is the most common shape in a long bull market.

Key figures

Price$120.30
Market cap$24.5B
P/E ratio64.0x
Return on invested capital20.6%
Gross margin92.8%
Debt to equity0.01x
Free cash flow yield7.0%
Growth rate used14.0%
Growth rate measured14.0%
Exit multiple assumed28.1x

How it compares

CompanyMoatBuy price
Alnylam Pharmaceuticals (ALNY)72$297.00
Jazz Pharmaceuticals Plc (JAZZ)53$351.09
Halozyme Therapeutics Inc (HALO)73$114.53
Bio-Techne (TECH)50$20.56

Be in the know

Subscribe to our Substack for deeper insights on value plays.

Subscribe free

Run your own assumptions

Every number above is built on assumptions that can be changed. In Moatly you can move the growth rate, the exit multiple and the margin of safety and watch every figure recalculate, so you are testing your own view of Incyte rather than accepting ours.

Download on the App StoreGet it on Google Play

Not investment advice. Estimates only, built on stated assumptions that could be wrong. Figures are drawn from reported financial statements and were current as of the date shown. Do your own research.